A61K 31/567
Substituted in position 17 alpha
Official title: substituted in position 17 alpha, e.g. mestranol, norethandrolone
A61K31/567 (Substituted in position 17 alpha) appears on 481 US grants and 849 published applications in this corpus.
Search patents in A61K- Granted patents
- 481
- Published applications
- 849
- Assignees
- 339
- Inventors
- 1,195
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 4 | 0 |
| 1977 | 0 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 1 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 1 | 0 |
| 1991 | 1 | 0 |
| 1992 | 1 | 0 |
| 1993 | 2 | 0 |
| 1994 | 1 | 0 |
| 1995 | 4 | 0 |
| 1996 | 14 | 0 |
| 1997 | 7 | 0 |
| 1998 | 10 | 0 |
| 1999 | 11 | 0 |
| 2000 | 7 | 0 |
| 2001 | 6 | 4 |
| 2002 | 9 | 20 |
| 2003 | 9 | 32 |
| 2004 | 7 | 32 |
| 2005 | 4 | 31 |
| 2006 | 6 | 24 |
| 2007 | 4 | 19 |
| 2008 | 5 | 34 |
| 2009 | 5 | 19 |
| 2010 | 9 | 17 |
| 2011 | 13 | 20 |
| 2012 | 14 | 29 |
| 2013 | 20 | 28 |
| 2014 | 20 | 49 |
| 2015 | 22 | 43 |
| 2016 | 26 | 44 |
| 2017 | 27 | 38 |
| 2018 | 24 | 43 |
| 2019 | 30 | 40 |
| 2020 | 29 | 45 |
| 2021 | 26 | 46 |
| 2022 | 27 | 57 |
| 2023 | 23 | 46 |
| 2024 | 19 | 27 |
| 2025 | 17 | 36 |
| 2026 | 15 | 26 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Preparation for ethinylestradiol-cyclodextrin complex and use thereof15 Sep 2026US 12,734,178 B2National Research Institute for Family Planning
- Ophthalmic device11 Aug 2026US 12,702,587 B2aVISI Ltd.
- System for providing birth control11 Aug 2026US 12,702,641 B2The Population Council, Inc.
- Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency28 Jul 2026US 12,691,127 B2Corcept Therapeutics, Inc.
- Altrenogest injection and preparation method and use thereof21 Jul 2026US 12,685,737 B2Ningbo Sansheng Biological Technology Co., Ltd.
- Combination of capivasertib, a cdk4/6 inhibitor and fulvestrant for use in the treatment of breast cancer8 Oct 2026US 2026/0306495 A1
- Misoprostol formulation for non-oral administration8 Oct 2026US 2026/0306508 A1Conceptra Biosciences, LLC
- Lysine acetyltransferase 6a (kat6a) inhibitor, combinations and uses thereof1 Oct 2026US 2026/0294884 A1Insilico Medicine IP Limited
- Cdk inhibitor and crystal form of pharmaceutically acceptable salt thereof, and use thereof24 Sep 2026US 2026/0285879 A1CSPC Ouyi Pharmaceutical Co., Ltd
- Levonorgestrel and compositions comprising the same17 Sep 2026US 2026/0272825 A1
Most cited
By later US patents
- Solid matrix system for transdermal drug delivery143US 5,770,219 ACygnus, Inc. · 1998
- Transdermal estrogen/progestin dosage unit, system and process136US 4,906,169 ARutgers, The State University of New Jersey · 1990
- Transdermal contraceptive formulations122US 4,816,258 AAlza Corporation · 1989
- Solid matrix system for transdermal drug delivery122US 5,252,334 ACygnus Therapeutic Systems · 1993
- Estrogenic compounds as anti-angiogenic agents112US 5,504,074 AChildren's Medical Center Corporation · 1996